Management of Barrett's Esophagus and Associated Dysplasia

Barrett’s oesophagus represents a metaplastic change of the distal oesophageal lining that predisposes to dysplasia and oesophageal adenocarcinoma. Management encompasses risk stratification, surveillance endoscopy, endoscopic therapy and adjunctive medical approaches. Patients without dysplasia undergo periodic high-resolution endoscopic examination with targeted biopsies, whereas those with low-grade dysplasia may be offered endoscopic ablation to minimise progression. High-grade dysplasia and early neoplasia are treated preferentially by endoscopic mucosal resection of visible lesions followed by radiofrequency ablation of the remaining Barrett’s mucosa to achieve complete eradication. Chemopreventive regimens, notably high-dose proton-pump inhibitors and aspirin, have demonstrated moderate efficacy in reducing neoplastic progression. More recently, molecular imaging agents and minimally invasive cell sampling devices have been developed to improve dysplasia detection and refine surveillance intervals. Genomic and copy-number profiling of Barrett’s tissues reveal that chromosomal instability and clonal diversity serve as biomarkers of malignant potential, guiding personalised monitoring and early intervention strategies. Collectively, these advances are reshaping a management paradigm that integrates precise endoscopic techniques, targeted ablation, molecular diagnostics and chemoprevention to avert progression to invasive cancer.

Research from Nature Portfolio

Recent studies employing multiregional whole-genome sequencing have elucidated the emergence and evolution of chromosomal instability in Barrett’s oesophagus. Analysis of copy-number trajectories in dysplastic and early cancerous foci revealed that whole-genome duplication events and breakage-fusion-bridge cycles drive clonal expansion following p53 inactivation. Identification of “sloping” copy-number variation provides a novel biomarker of ongoing genomic instability preceding overt neoplastic transformation. Foundational single-cell analyses have further demonstrated that genetic diversity within Barrett’s segments exists in a dynamic equilibrium, with rare clonal sweeps and slow lateral expansion of premalignant clones. Baseline genetic heterogeneity, rather than selective clonal drives, predicts future progression, suggesting that malignant potential may be predetermined at the time of Barrett’s emergence.

Management of Barrett's Esophagus and Associated Dysplasia publication trend

The graph below shows the total number of articles in management of barrett's esophagus and associated dysplasia across all publications each year (not limited to Nature Index journals).

Technical terms

Barrett’s oesophagus: Metaplastic transformation of oesophageal squamous epithelium into columnar intestinal-type mucosa.

Dysplasia: Premalignant epithelial abnormality graded as low or high based on architectural and cytological atypia.

Endoscopic mucosal resection (EMR): Technique to remove visible lesions from the mucosal layer for histological staging.

Radiofrequency ablation (RFA): Thermal ablation method using radiofrequency energy to eradicate residual Barrett’s epithelium.

Chromosomal instability: Ongoing acquisition of structural and numerical chromosome alterations in precancerous cells.

Fluorescence molecular endoscopy: Endoscopic imaging modality using fluorescent probes to highlight molecular targets in vivo.

Cytosponge: Minimally invasive cell collection device consisting of a sponge on a string to sample oesophageal lining.

References

1. Genomic signatures of past and present chromosomal instability in Barrett’s esophagus and early esophageal adenocarcinoma. Nature Communications (2023).
2. Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus. Nature Communications (2016).
3. PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma. Journal of Experimental & Clinical Cancer Research (2024).
4. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. The Lancet (2020).
5. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. The Lancet (2018).
6. Long-term outcomes after endoscopic treatment for Barrett’s neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period. Gut (2021).